About

Philippe Daull, PhD, Co-Founder and Chief Executive Officer of Akrivision Technologies, holds an MSc in chemistry and biology from the University of Strasbourg, France, and a PhD in cell biology from the University of Sherbrooke, QC, Canada. Dr Daull has over 20 years of industry experience, developing ophthalmic drugs and medical devices for the treatment of anterior and posterior eye segment pathologies (dry eye, glaucoma, macular oedema, diabetic retinopathy).

He is experienced in drug development process, from early-stage preclinical studies to translational research, in the preparation of regulatory documents for IND, IMPD, MAA and CE-marked dossiers, and at interacting with regulatory agencies (pre-IND, scientific advice meetings, etc). Dr Daull is the co-author of over 40 peer-reviewed scientific articles, book chapters and is the co-inventor of multiple patents.